BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives

Reuters
05 Feb
BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives

Feb 5 (Reuters) - Zenas Biopharma Inc ZBIO.O:

  • ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MULTIPLE SCLEROSIS (MOONSTONE) EXPECTED IN Q3 2025

  • ZENAS BIOPHARMA :TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL IN IMMUNOGLOBULIN G4-RELATED DISEASE (INDIGO) EXPECTED YEAR-END 2025

Source text: ID:nGNX3GBN3c

Further company coverage: ZBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10